Currently out of the existing stock ratings of Ian Somaiya, 54 are a BUY (71.05%), 22 are a HOLD (28.95%).

Ian Somaiya

Work Performance Price Targets & Ratings Chart

Analyst Ian Somaiya, currently employed carries an average stock price target met ratio of 67.76% that have a potential upside of 30.57% achieved within 645 days. Previously, Ian Somaiya worked at BMO, NOMURA.

Ian Somaiya’s has documented 159 price targets and ratings displayed on 10 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on BMRN, Biomarin Pharmaceutical at 23-Feb-2018.

Wall Street Analyst Ian Somaiya

Analyst best performing recommendations are on BIIB (BIOGEN).
The best stock recommendation documented was for BIIB (BIOGEN) at 8/1/2016. The price target of $304 was fulfilled within 1 day with a profit of $25.98 (9.34%) receiving and performance score of 93.45.

Average potential price target upside

of $61.78 (49.14%) on AMGN (AMGEN).
of $53.36 (19.39%) on BIIB (BIOGEN).
of $37.47 (41.78%) on CELG (CELGENE).

ALXN Alexion Pharmaceuticals AMGN Amgen BIIB Biogen BMRN Biomarin Pharmaceutical CELG Celgene GILD Gilead Sciences INCY yte NBIX Neurocrine Biosciences TTPH Tetraphase Pharmaceuticals ICPT Intercept Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hartaj Singh (OPPENHEIMER)